Abstract: A compound as a BTK inhibitor or an HER2 inhibitor, a preparation method therefor, and a use thereof. The compound comprises a structure as shown in formula II or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, or a mixture form thereof, and a pharmaceutically acceptable hydrate, a solvate, or salt. The BTK protein kinase inhibitor of the present invention has strong inhibitory activity on wild-type BTK or mutated BTK (C481S), and some of the compounds have high brain permeability; the HER2 inhibitor of the present invention has good HER2 kinase inhibitory activity and high blood-brain barrier transmittance; and the compound of the present invention has good pharmacokinetic properties and a good application prospect.

Abstract: A compound serving as a BTK inhibitor, a preparation method therefor, and a use thereof. The compound has a structure represented by formula I, or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof, or a pharmaceutically acceptable hydrate, solvent, or salt thereof, wherein A1, A2, A3, A4, A5 and A6 are each independently selected from C—R5 and N, and at least one of those is N; and M is selected from substituted or unsubstituted saturated or heterosaturated hydrocarbyl, substituted or unsubstituted unsaturated cyclic group or heterocyclyl, and substituted or unsubstituted monocyclic, bicyclic, or tricyclic aryl or heteroaryl. The provided BTK protein kinase inhibitor has strong inhibition for wild BTK and mutated BTK (C481S), has good pharmacokinetic properties, and has good application prospects.

Abstract: An azazinoindazole derivative represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, a prodrug thereof, a solvate thereof or a hydrate thereof are presented. The described compound may be used as a 5-HT3 receptor modulator. Experiments have proven that the compound of the preparation example has a strong affinity to 5-HT3 receptors, and has high activity as a modulator of 5-HT3 receptors. The compound may be used to prepare a drug for treating irritable bowel syndrome, nausea, vomiting, gastroenteritis, gastric dysfunction, diarrhea, pain, carcinoid syndrome, drug addiction and other diseases.